The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer
Abstract
PURPOSE: To address the role of positron emission tomography (PET) using [18 F]fluorodeoxyglucose (FDG) to monitor primary (neoadjuvant) chemotherapy in patients with locally advanced breast cancer. PATIENTS AND METHODS: Quantification of regional FDG uptake of the breast acquired after the first and second courses of chemotherapy was compared with the baseline scan in 22 patients with a total of 24 breast carcinomas. To evaluate the predictive value of PET imaging, histopathologic response after completion of chemotherapy classified as gross residual disease (GRD) or minimal residual disease (MRD) served as the gold standard. RESULTS: Significant differences in tracer uptake between nonresponding tumors (GRD) and responding lesions (MRD) were observed (P < .05) as early as after the first course of chemotherapy. Tracer uptake showed little change in tumors with GRD found later in pathologic analysis but decreased sharply to the background level in most tumors with MRD. After the first course, all responders were correctly identified (sensitivity 100%, specificity 85%) by a standardized uptake value decrease below 55% of the baseline scan. At this threshold, histopathologic response could be predicted with an accuracy of 88% and 91% after the first and second courses of therapy, respectively. CONCLUSION: This study demonstrates that in patients with advanced breast cancer undergoing primary chemotherapy, FDG-PET differentiates responders from nonresponders early in the course of therapy. This may help improve patient management by avoiding ineffective chemotherapy and supporting the decision to continue dose-intensive preoperative chemotherapy in responding patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
Hamacher, K., Coenen, H. H., & Stöcklin, G. (1986) · PubMed · Cited by 1,351
Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330
Wahl, R. L., Zasadny, K., Helvie, M., Hutchins, G. D., Weber, B., & Cody, R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2101 · Cited by 605
Gallagher, B. M., Fowler, J. S., Gutterson, N. I., MacGregor, R. R., Wan, C.-N., & Wolf, A. P. (1978) · PubMed · Cited by 557
Som, P., Atkins, H. L., Bandoypadhyay, D., Fowler, J. S., MacGregor, R. R., Matsui, K., Oster, Z. H., Sacker, D. F., Shiue, C. Y., Turner, H., et al. (1980) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198012000-00045 · Cited by 504
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
Rigo, P., Paulus, P., Kaschten, B. J., Hustinx, R., Bury, T., Jerusalem, G., Benoit, T., & Foidart-Willems, J. (1996) · European Journal of Nuclear Medicine · doi:10.1007/bf01249629 · Cited by 501
Wahl, R. L., Cody, R. L., Hutchins, G. D., & Mudgett, E. E. (1991) · Radiology · doi:10.1148/radiology.179.3.2027989 · Cited by 431
Scholl, S. M., Fourquet, A., Asselain, B., Pierga, J. Y., Vilcoq, J. R., Durand, J. C., Dorval, T., Palangié, T., Jouve, M., Beuzeboc, P., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90537-1 · Cited by 424
Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Adler, L. P., Crowe, J. P., al-Kaisi, N. K., & Sunshine, J. L. (1993) · Radiology · doi:10.1148/radiology.187.3.8497624 · Cited by 372
Higashi, K., Clavo, A. C., & Wahl, R. L. (1993) · PubMed · Cited by 310
Dehdashti, F., Flanagan, F. L., Mortimer, J. E., Katzenellenbogen, J. A., Welch, M. J., & Siegel, B. A. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050359 · Cited by 290
Mauriac, L., Durand, M., Avril, A., & Dilhuydy, J.-M. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057953 · Cited by 268
Jansson, T., Westlin, J. E., Ahlström, H., Lilja, A., Långström, B., & Bergh, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1470 · Cited by 257
Moon, D. H., Maddahi, J., Silverman, D. H. S., Glaspy, J. A., Phelps, M. E., & Hoh, C. K. (1998) · PubMed · Cited by 249
Avril, N., Dose, J., Jänicke, F., Bense, S., Ziegler, S., Laubenbacher, C., Römer, W., Pache, H., Herz, M., Allgayer, B., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1848 · Cited by 242
Self-citationAbraham, D. C., Jones, R. C., Jones, S. E., Cheek, J. H., Peters, G. N., Knox, S. M., Grant, M. D., Hampe, D. W., Savino, D. A., & Harms, S. E. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960701)78:1<91::aid-cncr14>3.0.co;2-2 · Cited by 236
Avril, N., Dose, J., Janicke, F., Ziegler, S., Romer, W., Weber, W., Herz, M., Nathrath, W., Graeff, H., & Schwaiger, M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.17.1204 · Cited by 213
Self-citationBassa, P., Kim, E. E., INOUE, T., Wong, F. C., Korkmaz, M., Yang, D. J., Wong, W., Hicks, K., Buzdar, A. U., & Podoloff, D. A. (1996) · PubMed · Cited by 198
Breast imaging with fluorine-18-FDG PET: quantitative image analysis.
Avril, N. E., Bense, S., Ziegler, S. I., Dose, J., Weber, W., Laubenbacher, C., Römer, W., Jänicke, F., & Schwaiger, M. (1997) · PubMed · Cited by 171
Self-citationRelevance of Positron Emission Tomography (PET) in Oncology
Weber, W., Avril, N. E., & Schwaiger, M. (1999) · Strahlentherapie und Onkologie · doi:10.1007/s000660050022 · Cited by 148
Self-citationMachiavelli, M. R., Romero, A. O., Pérez, J. E., Lacava, J. A., Domínguez, M. E., Rodriguez, R. J., Barbieri, M. R., Acuña, L. A. R., Acuña, J. M. R., Langhi, M. J., et al. (1998) · PubMed · Cited by 144
Cited by
(2001) · PubMed · Cited by 943
Breast MRI: guidelines from the European Society of Breast Imaging
Mann, R. M., Kuhl, C. K., Kinkel, K., & Boetes, C. (2008) · European Radiology · doi:10.1007/s00330-008-0863-7 · Cited by 839
Positron-Emission Tomography and Assessment of Cancer Therapy
Juweid, M. E., & Cheson, B. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050276 · Cited by 750
Weber, W. A., Ott, K., Becker, K., Dittler, H.-J., Helmberger, H., Avril, N. E., Meisetschläger, G., Busch, R., Siewert, J.-R., Schwaiger, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3058 · Cited by 701
Self-citationProgress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Metadata
- Authors
- Schelling, M., Avril, N., Nährig, J., Kuhn, W., Römer, W., Sattler, D., Werner, M., Dose, J., Jänicke, F., Graeff, H., & Schwaiger, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-04-08
- Volume
- 18
- Issue
- 8
- Pages
- 1689-1695
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1762109430
- Cited by
- 522
- References
- 24
- FWCI
- 27.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.